Australian Company Cortecs International has reduced its consolidated losses for the year ended June 30, 1994 by 2.2% to A$9.6 million ($7.12 million). Sales revenues amounted to A$10.2 million, down 2.6% following the disposal of the medical diagnostic business in November, 1994.
Cortecs said that turnover from the UK-based pharmaceutical marketing operations was flat at L4.7 million ($7.38 million). Operating profits grew 6% to L1.1 million. The company spent A$7 million on R&D during the year, which was the same as in fiscal 1993.
The year has been a busy one for the company, which has signed agreements with a variety of pharmaceutical companies relating to its Helisal rapid diagnostic kits. It also obtained a full listing on the London Stock Exchange in the UK, with a L15 million equity placement with institutional investors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze